Impact of minimal residual disease (MRD) status in clinical outcomes of patients with relapsed/refractory (R/R) acute lymphoblastic leukemia (ALL) treated with inotuzumab ozogamicin (InO) in the phase 3 INO-VATE trial.
Elias Jabbour(The University of Texas MD Anderson Cancer Center), Hagop M. Kantarjian(The University of Texas MD Anderson Cancer Center), Matthias Stelljes(University Hospital Münster), Erik Vandendries(Pfizer (United States)), Douglas Laird(Pfizer (United States)), Nicola Gökbuget(Goethe University Frankfurt), Giovanni Martinelli(Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori), Alexander Neuhof(Pfizer (Germany)), Daniel J. DeAngelo(Dana-Farber Cancer Institute), Anjali S. Advani(Cleveland Clinic), Michaela Liedtke(Cancer Prevention Institute of California), Wendy Stock(University of Chicago), Tao Wang(Chinese PLA General Hospital), Susan O’Brien(University of California, Irvine)
Cited by 6
Related Papers
International Consensus Classification of Myeloid Neoplasms and Acute Leukemias: integrating morphologic, clinical, and genomic data
|Blood|2022|2.7k
Targeting BTK with Ibrutinib in Relapsed Chronic Lymphocytic Leukemia
|New England Journal of Medicine|2013|2.2k
Anti-BCMA CAR T-Cell Therapy bb2121 in Relapsed or Refractory Multiple Myeloma
|New England Journal of Medicine|2019|1.7k
iwCLL guidelines for diagnosis, indications for treatment, response assessment, and supportive management of CLL
|Blood|2018|1.7k
Idelalisib and Rituximab in Relapsed Chronic Lymphocytic Leukemia
|New England Journal of Medicine|2014|1.7k